These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2210269)

  • 1. Is gastric acid hypersecretion the only reason for refractory gastroesophageal reflux disease?
    Savarino V; Mela GS; Zentilin P; Celle G
    Gastroenterology; 1990 Nov; 99(5):1542-3. PubMed ID: 2210269
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.
    Vela MF; Camacho-Lobato L; Srinivasan R; Tutuian R; Katz PO; Castell DO
    Gastroenterology; 2001 Jun; 120(7):1599-606. PubMed ID: 11375942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion.
    Kuipers EJ; Klinkenberg-Knol EC
    Gastroenterology; 1999 Feb; 116(2):479-83. PubMed ID: 9922329
    [No Abstract]   [Full Text] [Related]  

  • 4. Omeprazole failure in a patient with gastroesophageal reflux disease.
    Just R; Katzka DA; Castell DO
    Ann Intern Med; 1994 Dec; 121(11):899. PubMed ID: 7978711
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
    Omari TI; Haslam RR; Lundborg P; Davidson GP
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of H2-blockers and proton pump inhibitors on intragastric acidity and intraesophageal pH in patients with gastroesophageal reflux disease].
    Ivanov AN; Iakovenko EP; Iakovenko AV
    Eksp Klin Gastroenterol; 2004; (4):16-20, 107. PubMed ID: 15568661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease.
    Tefera S; Hatlebakk JG; Berstad A
    Am J Gastroenterol; 2001 Apr; 96(4):969-74. PubMed ID: 11316213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid pocket, hiatus hernia and acid reflux.
    McColl KE; Clarke A; Seenan J
    Gut; 2010 Apr; 59(4):430-1. PubMed ID: 20332515
    [No Abstract]   [Full Text] [Related]  

  • 10. Gastric acid hypersecretion in refractory gastroesophageal reflux disease.
    Collen MJ; Lewis JH; Benjamin SB
    Gastroenterology; 1990 Mar; 98(3):654-61. PubMed ID: 2298369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of cure of Helicobacter pylori infection on gastric acidity and gastroesophageal reflux: study by 24-h pH monitoring in patients with gastric or duodenal ulcer.
    Fukuchi T; Ashida K; Yamashita H; Kiyota N; Tsukamoto R; Takahashi H; Ito D; Nagamatsu R
    J Gastroenterol; 2005 Apr; 40(4):350-60. PubMed ID: 15870971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will impedence testing rewrite the book on GERD?
    Kahrilas PJ
    Gastroenterology; 2001 Jun; 120(7):1862-4. PubMed ID: 11375966
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
    Leite LP; Johnston BT; Just RJ; Castell DO
    Am J Gastroenterol; 1996 Aug; 91(8):1527-31. PubMed ID: 8759655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases.
    Leite LP; Just RJ; Castell DO; Lagerström PO
    Am J Gastroenterol; 1995 Oct; 90(10):1874-7. PubMed ID: 7572913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.
    Bell NJ; Hunt RH
    Gut; 1992 Jan; 33(1):118-24. PubMed ID: 1346769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
    Fiorucci S; Santucci L; Morelli A
    Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omeprazole, serum gastrin, and gastric acid suppression.
    Gideon RM; Paoletti V; Castell DO
    Ann Intern Med; 1995 Feb; 122(3):237-8. PubMed ID: 7810948
    [No Abstract]   [Full Text] [Related]  

  • 20. Omeprazole in the treatment of peptic ulcers and gastroesophageal reflux disease.
    Cappell MS
    N J Med; 1992 Oct; 89(10):762-4. PubMed ID: 1461581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.